News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
187.50 ^USD	-9.69%		-8.99%	+3.96%

Dec. 10	BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets	CI
Dec. 05	BeiGene, Ltd. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 09:30 AM

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets	Dec. 09	BU
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets	Dec. 09	CI
Jazz Pharmaceuticals Announces Ziihera Investor Webcast on December 11, 2024	Dec. 05	AQ
BeiGene, Ltd. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 09:30 AM	Dec. 05
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL	Dec. 04	BU
BeiGene, Ltd. and CLL Society Partner to Advance Test Before Treat? Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL	Dec. 04	CI
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024	Dec. 02	BU
BeiGene Insider Sold Shares Worth $9,190,570, According to a Recent SEC Filing	Dec. 02	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	Nov. 29	MT
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	Nov. 29	MT
Hong Kong Stocks End Week in Green; Mokingran Jewellery Gains 8% in Debut	Nov. 29	MT
BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%	Nov. 29	MT
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced, Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer	Nov. 28	AQ
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment	Nov. 27	DJ
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	Nov. 27	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data	Nov. 27	MT
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients	Nov. 27	MT
BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval	Nov. 27	DJ
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer	Nov. 27	BU
European Commission Approves BeiGene?s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer	Nov. 27	CI
BeiGene to Present at Upcoming Investor Conferences	Nov. 26	BU
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK	Nov. 21	DJ
Labcorp Holdings Finance Chief Glenn Eisenberg to Retire	Nov. 19	MT
Labcorp CFO Glenn Eisenberg Announces Plans to Retire	Nov. 19	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
BGNE Stock
News BeiGene, Ltd.